ClinicalTrials.gg
Active, not recruitingNCT04907799Updated Aug 12, 2025

Daily Caloric Restriction in ADPKD

An interventional study of Daily caloric restriction and Standard advice control in Autosomal Dominant Polycystic Kidney and Overweight and Obesity, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver — 1 open to participants now, 5 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · University of Colorado, Denver.

Enrollment
3rd of 11
125 · median 61
Started
2021
with 1 other
No phase
4 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 with no phase, and was the 9th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

1 of the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, or all of them as a file.
02

Study summary

This clinical trial will determine whether a daily-caloric restriction-based weight loss intervention can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat by magnetic resonance imaging. Blood and fat samples will provide insight into biological changes that may contribute to any observed benefits of the intervention.

Read the detailed description

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by development and continued growth of numerous fluid-filled renal cysts that ultimately result in renal failure. Similar to the general population, the prevalence of overweight and obesity have been rising in ADPKD patients, effecting about two-thirds of individuals. Adipocytes do not simply act as a fat reservoir, but are active endocrine organs that promote release of pro-inflammatory cytokines, and thus, may be a promising clinical target for ADPKD management. Mounting evidence also suggests that a metabolic defect exists in ADPKD, which likely contributes to cystic epithelial proliferation and subsequent cyst growth. Additionally, the investigators recently reported that overweight and obesity are strong independent predictors of more rapid kidney growth. Collectively, these data suggest that interventions to reduce abdominal adiposity may slow ADPKD progression.

Initial results from the investigators' R03-funded pilot and feasibility study support that a 12-month daily caloric restriction (DCR)-based behavioral weight loss intervention in adults with ADPKD and overweight or obesity: 1) is feasible and acceptable; 2) slowed kidney growth (annual %∆ in height-adjusted TKV [htTKV]), which was highly correlated with weight loss; 3) reduced abdominal adiposity; and 4) altered pathways implicated in ADPKD progression and metabolism. These initial results suggest that a DCR-based behavioral weight loss intervention offers a promising strategy to slow ADPKD progression. However, the pilot and feasibility study was limited by a small sample size, relatively short duration, and lack of a control group. Thus, to translate these promising results of the pilot study towards clinical practice, the investigators are conducting a randomized, controlled clinical trial in a larger number of adults with ADPKD and overweight or obesity to directly compare the efficacy of a DCR-based behavioral weight loss intervention compared to control for slowing kidney growth (primary outcome) over a longer duration. Changes in abdominal adiposity will serve as a secondary outcome and effects of weight loss on circulating and adipose markers of biological pathways will provide mechanistic insight.

In a subset of participants recruited for this clinical trial, we will measure change in kidney oxidative metabolism, insulin sensitivity, plasma metabolomics, and gut microbiota. These additional measures will aim to compare kidney oxidative metabolism, insulin sensitivity, plasma metabolome and gut microbiota at baseline and 2 years. In addition, the investigators aim to define the relations among changes in kidney oxidative metabolism, insulin sensitivity, plasma metabolome, gut microbiota, total kidney volume, and body weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure, substrate utilization, plasma metabolomics, or the gut microbiome.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age
  • ADPKD diagnosis based on the modified Pei-Ravine criteria
  • Body-mass index of 25-45 kg/m\^2
  • Estimated ≥ 30 mL/min/1.73m\^2
  • Total kidney volume (htTKV) > 600 mL, calculated/estimated from a previous kidney ultrasound or magnetic resonance imaging
  • Access to the internet with video chat capabilities
  • No plans for extended travel (>2 weeks) without internet access during the 12-month intensive period
  • Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Current smokers or history of smoking in the past 12 months
  • Alcohol dependence or abuse
  • History of hospitalization or major surgery within the last 3 months
  • Untreated dyslipidemia
  • Uncontrolled hypertension
  • Pregnancy, lactation, or unwillingness to use adequate
  • Cardiovascular disease, peripheral vascular disease, or symptoms suggestive of cardiovascular disease: chest pain, shortness of breath at rest or with mild exertion, syncope
  • Abnormal resting (ECG): serious arrhythmias, including multifocal premature ventricular contractions (PVC\'s), frequent PVC\'s (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC\'s), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, > 480 msec or other significant conduction defects
  • Significant pulmonary disease including: , interstitial lung disease, cystic fibrosis, or uncontrolled asthma
  • Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism unless weight stable
  • History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder
  • Weight loss of >5% in the past 3 months for any reason except post-partum weight loss; weight gain >5% requires assessment by PI
  • Major psychiatric disorder (e.g., psychosis, schizophrenia, mania, bipolar disorder) or current severe depression, based on criteria for Major Depressive Episode, which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions)
  • Inability to cooperate with or clinical for magnetic resonance imaging, including: severe claustrophobia, implants, devices, or non-removable body piercings
  • Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Daily Caloric Restriction

    The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.

    Behavioral: Daily caloric restriction

  • Other
    Standard Advice Control

    The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.

    Other: Standard advice control

Interventions

  • BehavioralDaily caloric restriction

    Weight loss based on daily caloric restriction and increased physical activity

  • OtherStandard advice control

    Initial nutrition consultation without subsequent counseling

06

What researchers measure

Primary outcomes

  1. Change in height-Adjusted Total kidney volume

    To assess kidney growth, we will measure height-adjusted total kidney volume by magnetic resonance imaging at baseline and 24 months to determine annual percent change.

    Time frame: Baseline, 24-months

Secondary outcomes

  1. Change in abdominal adiposity

    Abdominal adiposity (subcutaneous, visceral, and total) will be assessed by magnetic resonance imaging.

    Time frame: Baseline, 24-months

  2. Change in the ratio of insulin-like growth factor-1 (IGF-1)/ to GF binding protein-1

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 12-months, 24-months

  3. Change in adiponectin (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 12-months, 24-months

  4. Change in leptin (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 12-months, 24-months

  5. Change in interleukin-6 (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 12-months, 24-months

  6. Change in tumor necrosis factor-alpha (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 12-months, 24-months

  7. Change in C-reactive protein (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 12-months, 24-months

  8. Change in peripheral blood mononuclear cell protein expression of pAMPK/AMPK

    PBMCs will be isolated from whole blood to assess protein expression

    Time frame: Baseline, 12-months, 24-months

  9. Change in peripheral blood mononuclear cell protein expression of pS6K/S6K

    PBMCs will be isolated from whole blood to assess protein expression

    Time frame: Baseline, 12-months, 24-months

  10. Change in adiponectin (adipose tissue)

    A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.

    Time frame: Baseline, 24-months

  11. Change in leptin (adipose tissue)

    A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.

    Time frame: Baseline, 24-months

  12. Change in interleukin-6 (adipose tissue)

    A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.

    Time frame: Baseline, 24-months

  13. Change in tumor necrosis factor-alpha (adipose tissue)

    A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker.

    Time frame: Baseline, 24-months

  14. Change in renal oxygen consumption

    Renal oxygen consumption will be assessed by a PET/CT scan using 11-C acetate in a sub-set of participants

    Time frame: Baseline, 24-months

  15. Change in gut microbiota

    16S rRNA gene sequencing will be used for taxonomic characterization of the gut microbiota in a subset of participants.

    Time frame: Baseline, 24-months

  16. Change in plasma metabolome

    Untargeted plasma metabolomics will be performed using high-performance liquid chromatography-tandem mass spectrometry in a subset of participants.

    Time frame: Baseline, 24-months

Other outcomes

  1. Safety (adverse events)

    Number of participants with treatment-related adverse events in each group as evaluated by the DSMB

    Time frame: 24-months

  2. Change in dietary Energy Intake

    Multiple pass 24-hr dietary recalls will be analyzed to evaluate self-reported energy intake

    Time frame: Baseline, 1-, 6-, 12-, and 24-months

  3. Adherence

    Self-reported dietary adherence using a 1-10 likert scale (10 is highest adherence)

    Time frame: 24 months

  4. Tolerability (dropout due to adverse events)

    Subject dropout due to treatment-emergent adverse events

    Time frame: 24 months

  5. Change in free-living physical activity

    Estimated energy expenditure (METs) over a 7-day period will be quantified using the activPAL3 micro.

    Time frame: Baseline, 6-, 12- and 24-months

  6. Change in percent body fat

    Percent body fat will be assessed via DEXA scan in a sub-set of participants.

    Time frame: Baseline, 24-months

  7. Change in plasma choline

    Plasma choline will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants.

    Time frame: Baseline, 24-months

  8. Change in plasma trimethylamine

    Plasma trimethylamine will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants.

    Time frame: Baseline, 24-months

  9. Change in plasma trimethylamine-N-oxide

    Plasma trimethylamine-N-oxide will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants.

    Time frame: Baseline, 24-months

07

Study locations

1 site
08

References and documents

Publications

  • Cortinovis M, Perico N, Remuzzi G. The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care. Clin J Am Soc Nephrol. 2025 Dec 5. doi: 10.2215/CJN.0000000975. Online ahead of print. PubMed 41348481 ↗
  • Nowak KL, Copeland TP, Ku E, Sarnak MJ, Gitomer B, Abebe KZ, Chapman A, Perrone R, Rahbari-Oskoui FF, Steinman T, Yu ASL, Chonchol M. Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2025 Apr 1;20(4):520-528. doi: 10.2215/CJN.0000000640. Epub 2025 Feb 19. PubMed 39970002 ↗
  • Chebib FT, Nowak KL, Chonchol MB, Bing K, Ghanem A, Rahbari-Oskoui FF, Dahl NK, Mrug M. Polycystic Kidney Disease Diet: What is Known and What is Safe. Clin J Am Soc Nephrol. 2024 May 1;19(5):664-682. doi: 10.2215/CJN.0000000000000326. Epub 2023 Sep 20. PubMed 37729939 ↗

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in ADPKD. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. data use agreement) are prerequisites to the sharing of data with the requesting party.

Supporting information: Study protocol, Informed consent form

Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jun 2027, 67 months after the start.

Of 23 interventional studies with no phase under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 54. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
Jun 1, 2021
StartActual
Nov 3, 2021
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04907799
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Nov 3, 2021
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 12, 2025

Study contacts

Kristen Nowak, PhD, MPH
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion